Drug Trial Radar · NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,023
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Oct 29, 2031
Study completion Oct 29, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Conditions
- Cervical Cancer
Interventions
PembrolizumabBiological
Intravenous (IV) Infusion
Sacituzumab TirumotecanBiological
IV Infusion
BevacizumabBiological
IV Infusion
PaclitaxelDrug
IV Infusion
CisplatinDrug
IV Infusion
CarboplatinDrug
IV Infusion
Rescue MedicationsDrug
Participants will receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent, prophylactic steroid mouthwash (dexamethasone or equivalent), and granulocyte colony-stimulating factor (G-CSF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 69 months
- Part 1 Safety Run-in: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 66 months
- Part 2 Maintenance Treatment: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 48 months
- Part 2 Maintenance Treatment: Overall Survival (OS)Time frame: Up to approximately 60 months
Locations
189 sites in 29 countries. Site status is shown where the registry gives one.
University of Alabama- Birmingham ( Site 5015)
Birmingham, Alabama · Recruiting
Alaska Womens Cancer Care ( Site 5046)
Anchorage, Alaska · Recruiting
CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037)
Irvine, California · Recruiting
Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 5000)
La Jolla, California · Recruiting
University of California Irvine Medical Center ( Site 6006)
Orange, California · Recruiting
Florida Cancer Specialists - South ( Site 7001)
Fort Myers, Florida · Recruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 5043)
Miami Beach, Florida · Recruiting
Moffit Cancer Center ( Site 5026)
Tampa, Florida · Recruiting
Florida Cancer Specialists - East ( Site 7000)
West Palm Beach, Florida · Recruiting
Winship Cancer Institute of Emory University ( Site 5005)
Atlanta, Georgia · Recruiting
Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005)
Savannah, Georgia · Recruiting
TRIALS 365 ( Site 6008)
Shreveport, Louisiana · Recruiting
Maryland Oncology Hematology (MOH) ( Site 8001)
Columbia, Maryland · Recruiting
Minnesota Oncology Hematology, PA ( Site 8003)
Edina, Minnesota · Recruiting
Nebraska Methodist Hospital ( Site 5010)
Omaha, Nebraska · Recruiting
Women's Cancer Center of Nevada ( Site 6011)
Las Vegas, Nevada · Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5039)
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009)
New York, New York · Recruiting
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 5020)
Cincinnati, Ohio · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6002)
Columbus, Ohio · Recruiting
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001)
Tulsa, Oklahoma · Recruiting
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)
Eugene, Oregon · Recruiting
Honickman Center ( Site 5033)
Philadelphia, Pennsylvania · Recruiting
Asplundh Cancer Pavilion ( Site 5002)
Willow Grove, Pennsylvania · Recruiting
Women & Infants Hospital ( Site 6003)
Providence, Rhode Island · Recruiting
University of Tennessee Medical Center ( Site 6012)
Knoxville, Tennessee · Recruiting
Texas Oncology - DFW ( Site 8005)
Fort Worth, Texas · Recruiting
Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010)
Houston, Texas · Recruiting
Texas Oncology-The Woodlands ( Site 8000)
The Woodlands, Texas · Recruiting
Texas Oncology - Northeast Texas ( Site 8002)
Tyler, Texas · Recruiting
University of Virginia Cancer Center ( Site 5044)
Charlottesville, Virginia · Recruiting
Inova Schar Cancer Institute ( Site 5045)
Fairfax, Virginia · Recruiting
Centro Medico Privado CEMAIC ( Site 0102)
Córdoba, Argentina · Recruiting
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0111)
La Rioja, Argentina · Recruiting
Centro de Oncología e Investigación de Buenos Aires ( Site 0107)
Berazategui, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0105)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Fundación Respirar ( Site 0101)
Belgrano, Buenos Aires F.D., Argentina · Recruiting
Instituto Misionero del Cancer ( Site 0112)
Posadas, Misiones Province, Argentina · Recruiting
Instituto de Oncologia de Rosario ( Site 0104)
Rosario, Santa Fe Province, Argentina · Recruiting
Hospital Provincial del Centenario ( Site 0106)
Rosario, Santa Fe Province, Argentina · Recruiting
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.